Drug trial extends hope for patients with rare blood disorders
NCT ID NCT06351631
Summary
This study continues treatment for 400 people with rare blood cancers who are already benefiting from the drug bomedemstat in earlier trials. Its main goal is to collect long-term safety information and see how well the drug continues to control the disease over time. The study is open to participants who have safely taken the drug for at least six months and are seeing clinical benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aotearoa Clinical Trials ( Site 1400)
ACTIVE_NOT_RECRUITINGAuckland, 2025, New Zealand
-
Azienda Ospedaliera Universitaria Careggi ( Site 2700)
RECRUITINGFlorence, Tuscany, 50134, Italy
Contact Phone: •••-•••-••••
-
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
RECRUITINGAlessandria, 15121, Italy
Contact Phone: •••-•••-••••
-
Boston Pilgrim Hospital ( Site 3403)
RECRUITINGBoston, Lincolnshire, PE21 9QS, United Kingdom
Contact Phone: •••-•••-••••
-
DUHS Duke Blood Cancer Center ( Site 6005)
RECRUITINGDurham, North Carolina, 27705, United States
Contact Phone: •••-•••-••••
-
Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
RECRUITINGSouthport, Queensland, 4215, Australia
Contact Phone: •••-•••-••••
-
Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
RECRUITINGLondon, London, City of, SE1 9RT, United Kingdom
Contact Phone: •••-•••-••••
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
RECRUITINGBologna, 40138, Italy
Contact Phone: •••-•••-••••
-
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
RECRUITINGLondon, Hammersmith and Fulham, W12 0HS, United Kingdom
Contact Phone: •••-•••-••••
-
Monash Health ( Site 1004)
RECRUITINGClayton, Victoria, 3168, Australia
Contact Phone: •••-•••-••••
-
North Shore Hospital-Department of Haematology ( Site 1401)
ACTIVE_NOT_RECRUITINGAuckland, 0622, New Zealand
-
Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
RECRUITINGVarese, 21100, Italy
Contact Phone: •••-•••-••••
-
Queen Mary Hospital ( Site 1601)
ACTIVE_NOT_RECRUITINGHksar, Hong Kong
-
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-••••
-
Royal North Shore Hospital ( Site 1001)
RECRUITINGSt Leonards, New South Wales, 2065, Australia
Contact Phone: •••-•••-••••
-
Royal Prince Alfred Hospital ( Site 1003)
RECRUITINGCamperdown, New South Wales, 2050, Australia
Contact Phone: •••-•••-••••
-
Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
RECRUITINGBuderim, Queensland, 4556, Australia
Contact Phone: •••-•••-••••
-
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-••••
-
UPMC Hillman Cancer Center ( Site 6004)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-••••
-
University College London Hospital ( Site 3400)
RECRUITINGLondon, London, City of, NW1 2PG, United Kingdom
Contact Phone: •••-•••-••••
-
University of Michigan ( Site 6000)
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.